2022 in cancer

FDA · US: 165 records / 66 drugsHealth Canada · CA: 50 records / 30 drugsEMA · EU: 23 records / 23 drugs

• Dec 22, 2022Mosunetuzumab FDA · US original application accelerated approved Follicular LymphomaLUNSUMIO is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after…openfda
• Dec 15, 2022Bendamustine FDA · US original application approved Chronic Lymphocytic LeukemiaChronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.openfda
• Dec 15, 2022Bendamustine FDA · US original application approved Indolent B-Cell Non-Hodgkin LymphomaIndolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.openfda
• Dec 12, 2022Adagrasib FDA · US original application approved Malignant Colorectal NeoplasmColorectal cancer (CRC)* • In combination with cetuximab, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic CRC, as…openfda
• Dec 12, 2022Adagrasib FDA · US original application approved Lung Non-Small Cell CarcinomaNon-small cell lung cancer (NSCLC)* • As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as…openfda
• Dec 7, 2022Bendamustine FDA · US original application approved Chronic Lymphocytic LeukemiaChronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.openfda
• Dec 7, 2022Bendamustine FDA · US original application approved Indolent B-Cell Non-Hodgkin LymphomaIndolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1 )openfda
• Dec 7, 2022Bendamustine FDA · US original application approved Indolent B-Cell Non-Hodgkin LymphomaIndolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.openfda
• Dec 1, 2022Olutasidenib FDA · US original application approved Acute Myeloid LeukemiaRelapsed or Refractory Acute Myeloid Leukemia REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia…openfda
• Nov 29, 2022Methotrexate FDA · US original application approved Acute Lymphoblastic LeukemiaTreatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimenopenfda
• Nov 29, 2022Methotrexate FDA · US original application approved Mycosis FungoidesTreatment of adults with mycosis fungoidesopenfda
• Nov 29, 2022Methotrexate FDA · US original application approved Mycosis FungoidesTreatment of adults with mycosis fungoidesopenfda
• Nov 29, 2022Methotrexate FDA · US original application approved Mycosis FungoidesTreatment of adults with mycosis fungoidesopenfda
• Nov 29, 2022Methotrexate FDA · US original application approved Non-Hodgkin LymphomaTreatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimenopenfda
• Nov 29, 2022Methotrexate FDA · US original application approved Non-Hodgkin LymphomaTreatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimenopenfda
• Nov 29, 2022Methotrexate FDA · US original application approved Non-Hodgkin LymphomaTreatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimenopenfda
• Nov 29, 2022Methotrexate FDA · US original application approved Acute Lymphoblastic LeukemiaTreatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimenopenfda
• Nov 29, 2022Methotrexate FDA · US original application approved Non-Hodgkin LymphomaTreatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimenopenfda
• Nov 29, 2022Methotrexate FDA · US original application approved Acute Lymphoblastic LeukemiaTreatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimenopenfda
• Nov 29, 2022Methotrexate FDA · US original application approved Mycosis FungoidesTreatment of adults with mycosis fungoidesopenfda
• Nov 29, 2022Methotrexate FDA · US original application approved Acute Lymphoblastic LeukemiaTreatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimenopenfda
• Nov 22, 2022Docetaxel FDA · US original application approved Gastric AdenocarcinomaGastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junctionopenfda
• Nov 22, 2022Docetaxel FDA · US original application approved Head and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHNopenfda
• Nov 22, 2022Docetaxel FDA · US original application approved Lung Non-Small Cell CarcinomaNon-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable,…openfda
• Nov 22, 2022Docetaxel FDA · US original application approved Malignant Breast NeoplasmBreast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant…openfda
• Nov 22, 2022Docetaxel FDA · US original application approved Castration-Resistant Prostate CarcinomaCastration- Resistant Prostate Cancer (CRPC) : with prednisone in metastatic CRPCopenfda
• Nov 14, 2022Mirvetuximab Soravtansine FDA · US original application approved Malignant Peritoneal NeoplasmELAHERE ® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or…openfda
• Oct 25, 2022Teclistamab FDA · US original application approved Multiple MyelomaTECVAYLI is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma in combination with daratumumab and hyaluronidase-fihj…openfda
• Oct 21, 2022Tremelimumab FDA · US original application approved Hepatocellular Carcinomain combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).openfda
• Sep 30, 2022Futibatinib FDA · US original application accelerated approved Intrahepatic CholangiocarcinomaLYTGOBI is indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma…openfda
• Aug 24, 2022Ibrutinib FDA · US original application approved Waldenstrom Macroglobulinemia. Adult patients with Waldenström’s macroglobulinemia (WM)openfda
• Aug 3, 2022Acalabrutinib FDA · US original application approved Mantle Cell LymphomaIn combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for…openfda
• Aug 3, 2022Acalabrutinib FDA · US original application approved Mantle Cell LymphomaIn combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for…openfda
• Jul 27, 2022Paclitaxel FDA · US original application approved Lung Non-Small Cell CarcinomaLocally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates…openfda
• Jul 27, 2022Paclitaxel FDA · US original application approved Pancreatic AdenocarcinomaMetastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.openfda
• Jul 27, 2022Bortezomib FDA · US original application approved Mantle Cell Lymphomatreatment of adult patients with mantle cell lymphomaopenfda
• Jul 27, 2022Bortezomib FDA · US original application approved Multiple Myelomatreatment of adult patients with multiple myelomaopenfda
• Jul 27, 2022Paclitaxel FDA · US original application approved Malignant Breast NeoplasmMetastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy…openfda
• Jun 22, 2022Pemetrexed FDA · US original application approved Lung Non-Squamous Non-Small Cell CarcinomaAs a single agent for the maintenance treatment of patients with locally advanced or metastatic, non -squamous NSCLC whose disease has not progressed after…openfda
• Jun 22, 2022Pemetrexed FDA · US original application approved Lung Non-Squamous Non-Small Cell CarcinomaAs a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.openfda
• Jun 22, 2022Pemetrexed FDA · US original application approved Pleural Malignant MesotheliomaInitial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not…openfda
• Jun 22, 2022Pemetrexed FDA · US original application approved Lung Non-Squamous Non-Small Cell CarcinomaIn combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC).openfda
• Jun 22, 2022Pemetrexed FDA · US original application approved Lung Non-Small Cell CarcinomaLimitations of Use : Pemetrexed Injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer.openfda
• May 26, 2022Pemetrexed FDA · US original application approved Lung Non-Squamous Non-Small Cell Carcinomaas a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.openfda
• May 26, 2022Pemetrexed FDA · US original application approved Lung Non-Small Cell CarcinomaLimitations of Use: Pemetrexed Injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer.openfda
• May 26, 2022Pemetrexed FDA · US original application approved Lung Non-Squamous Non-Small Cell Carcinomaas a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four…openfda
• May 26, 2022Pemetrexed FDA · US original application approved Lung Non-Squamous Non-Small Cell Carcinomain combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer…openfda
• May 26, 2022Pemetrexed FDA · US original application approved Pleural Malignant Mesotheliomainitial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not…openfda
• May 26, 2022Pemetrexed FDA · US original application approved Lung Non-Squamous Non-Small Cell Carcinomain combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.openfda
• May 2, 2022Bortezomib FDA · US original application approved Mantle Cell LymphomaTreatment of adult patients with mantle cell lymphoma.openfda
• May 2, 2022Bortezomib FDA · US original application approved Multiple MyelomaTreatment of adult patients with multiple myeloma.openfda
• Feb 25, 2022Filgrastim FDA · US original application approved Acute Myeloid LeukemiaReduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid…openfda
• Jan 25, 2022Tebentafusp FDA · US original application approved Uveal MelanomaKIMMTRAK is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. KIMMTRAK is a bispecific gp100…openfda
• Dec 12, 2022Adagrasib FDA · US original application accelerated approved cancer not stated in this record*These indications are approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for these…openfda
• Nov 29, 2022Methotrexate FDA · US original application approved cancer not stated in this recordTreatment of adults with rheumatoid arthritis • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) • Treatment of adults…openfda
• Nov 29, 2022Methotrexate FDA · US original application approved cancer not stated in this recordTreatment of adults with rheumatoid arthritis • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) • Treatment of adults…openfda
• Nov 29, 2022Methotrexate FDA · US original application approved cancer not stated in this recordTreatment of adults with rheumatoid arthritis • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) • Treatment of adults…openfda
• Nov 29, 2022Methotrexate FDA · US original application approved cancer not stated in this recordTreatment of adults with rheumatoid arthritis • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) • Treatment of adults…openfda
• Oct 21, 2022Tremelimumab FDA · US original application approved cancer not stated in this recordin combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no…openfda
• Aug 24, 2022Ibrutinib FDA · US original application approved cancer not stated in this recordAdult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) • . Adult patients with chronic lymphocytic leukemia (CLL)/Small…openfda

RegulatoryAll 2022 records with filters →

Studies

7,542

Interventional

5,663

Phase III

463

Industry-led

1,820

With posted results

367

Countries with sites

109

Published source: clinicaltrials · first_posted_date as posted